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Abstract  
The optimal timing of coronary angiography (CAG) in high-risk patients with acute coronary 
syndrome without persisting ST-segment elevation (NST-ACS) remains undetermined. The 
NONSTEMI (NON-ST-Elevation Myocardial Infarction) trial aimed to compare outcomes among 
NSTE-ACS patients randomized to acute CAG (STEMI-like approach) with patients  
randomized to medical therapy and subacute CAG. We randomized 496 patients with  
suspected NST-ACS based on symptoms and significant regional ST depressions  
and/or elevated point-of-care troponin T (POC-cTnT) (≥ 50 ng/l) to either acute CAG  
(< 2 h, n=245) or subacute CAG (< 72 h, n=251). The primary endpoint was a composite of all-
cause death, re-infarction, and readmission with congestive heart failure within 1 year from 
randomization. A final acute coronary syndrome (ACS) diagnosis was assigned to 429 (86.5%) 
patients. The median time from randomization to revascularization was 1.3 hours in the acute CAG 
group versus 51.1 hours in the subacute CAG group (P < 0.001). The composite endpoint occurred 
in 25 patients (10.2%) in the acute CAG group and 29 (11.6%) in the subacute CAG group, P = 
0.62. The acute CAG group had a 1-year all-cause mortality of 5.7% compared with 5.6% in the 
subacute CAG group, P = 0.96. In conclusion, neither the composite endpoint of all-cause death, re-
infarction, and readmission with congestive heart failure nor mortality differed between an acute 
and subacute CAG approach in NSTE-ACS patients. However, identification of NSTE-ACS 
patients in the prehospital phase and direct triage to an invasive centre is feasible, safe and may 
facilitate early diagnosis and revascularization.  
Key-words: 
Non-ST-segment myocardial infarction 
Troponin T 
Prehospital 
Early diagnosis 
Telemedicine 
Point-of-care systems 
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Introduction 
Current guidelines from the European Society of Cardiology (ESC) 2015 
1
 and the American 
Heart Association/American College of Cardiology (AHA/ACC) 2014 
2
 on the management of 
patients with NSTE-ACS recommend coronary angiography (CAG) within 24 hours in high-risk 
patients. It remains unknown whether high-risk patients with NSTE-ACS benefit from an ST-
elevation myocardial infarction (STEMI)-like management pathway that includes prehospital 
diagnosis, triage directly to an invasive centre, and acute CAG followed by primary percutaneous 
coronary intervention (PPCI), if indicated. The acute versus subacute angioplasty in patients with 
NON-ST-Elevation Myocardial Infarction (NONSTEMI) trial (clinicaltrials.gov: NCT01638806) 
was a randomized, open-labeled, 2-centre study that compared a STEMI-like management pathway 
with the routine standard of care according to current guidelines for NSTE-ACS patients 
1,2
. We 
analyzed phase 1 of the trial after inclusion of 250 patients and found that it was feasible to 
diagnose patients with NSTE-ACS in the prehospital phase or immediately upon hospital arrival 
3
. 
The aim of the present phase 2 and 3 of the trial was to investigate whether a STEMI-like pathway 
with acute CAG improved the outcome with regard to a composite endpoint comprising death of 
all-cause, re-infarction, and readmission with congestive heart failure (CHF) within 1 year from 
randomization.  
Methods  
The design of the NONSTEMI trial and the primary results from phase 1 describing the first 
250 patients have been reported previously 
3
. In short, patients were eligible for enrolment when 
they presented with ongoing chest pain and either significant ST-segment depressions in the 
electrocardiogram (ECG) or elevated point-of-care cardiac troponin T (POC-cTnT) (≥ 50 ng/l) in 
the prehospital phase or immediately upon hospital admission. Patients were randomized to either 
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acute CAG within 2 hours (subsequently referred to as “acute CAG group”) or medical treatment 
and subacute CAG within 72 hours (< 24 h if their Global Registry of Acute Coronary Events 
(GRACE) score > 140) according to ESC guidelines (subsequently referred to as the “subacute 
CAG group”) 
1
. While inclusion was ongoing, a software upgrade of the Cobas h232 instrument of 
1 December 2015 lowered the detection limit to 40 ng/l which from that point onwards was 
considered elevated. An independent event committee (see acknowledgements) had full access to 
the individual patient files and adjudicated the endpoints at 3 months and at the 12-month follow-
up.  
The primary endpoint was all-cause mortality and a composite endpoint of all-cause mortality,  
re-infarction or readmission with CHF within 1 year from randomization. The secondary endpoint 
comprised several elements: readmission with angina pectoris, readmission with stroke, non-
scheduled re-intervention, and bleeding within 1 year from randomization. Furthermore, the 
secondary endpoint included the rate and choice of revascularization, time from randomization to 
CAG and intervention, time to intervention, and total admission time during the index admission.  
We estimated the 1-year all-cause mortality in NSTEMI patients to 10%. Assuming an 
absolute reduction in all-cause mortality of 2.5% with an alpha of 0.05 and a power of 80%, we 
calculated that 2,000 patients were needed in each group to compare mortality. Given an estimated 
risk of the composite endpoint (all-cause mortality, re-infarction or readmission with CHF) of 15% 
within 1 year, we calculated the number of patients required to document a 4% reduction in the 
composite endpoint to be 1,109 patients in each group. To document a 1.5-day reduction in LOS, 
we calculated the number of patients required in each group to be 63.  
Each of the 3 phases was dimensioned as follows: Phase 1 was based on the first 250 patients 
and aimed to determine if a sufficient number of enrolled patients had a final diagnosis of ACS, 
which would qualify for continuation of the study. The results from phase 1 were published in 2016 
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3
. Phase 2 was based on the first 2,500 patients and aimed to compare the composite endpoint (all-
cause mortality, re-infarction or readmission with CHF) at 12 months from randomization. Phase 3 
was based on 4,500 patients and aimed to compare mortality. The study was initiated in June 2012. 
Because the recruitment rate was lower than expected, the trial was terminated prematurely by the 
study steering committee, due to futility, in March 2016 after inclusion of 500 patients. The present 
paper reports the endpoints planned for phases 2 and 3.  
The trial was performed in accordance with the Helsinki Declaration. The protocol was 
approved by the local ethics committee (Central Denmark Regional Ethical Committee) and the 
Danish Data Protection Agency. The trial is registered with ClinicalTrials.gov: NCT01638806. Data 
were analyzed by the intention-to-treat principle. Categorical data are presented as absolute 
numbers (percentages) and continuous variables are presented as medians with interquartile ranges. 
Differences between the groups were compared using the chi-squared test, the Wilcoxon rank-sum 
test, and the Kruskal–Wallis test as appropriate. We computed unadjusted Kaplan-Meier curves 
based on time-to-event (all-cause death and the composite event). The comparison was made using 
log-rank statistics. Tests were considered statistically significant if p-values were below 0.05 (2-
sided test). The statistical analyses were performed by MBR, CJT, and CS using Stata 13.1 (Stata 
Corporation, College Station, TX, USA). 
Results  
Of the 500 patients enrolled in the NONSTEMI trial, 247 were assigned to the acute CAG 
group and 253 to the subacute CAG group. The patient flow is shown in Figure 1.  Baseline 
characteristics and medical treatment pre-admission and during hospitalization did not differ 
between the 2 groups (Table 1). The majority of patients had an elevated POC-cTnT value at the 
time of enrolment as shown in Table 2. The final diagnosis confirmed by the Endpoint Committee 
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are listed in Table 2. ACS was confirmed in 429 (87%) cases and a total of 332 (67%) patients had 
Non-ST-Elevation Myocardial Infarction (NSTEMI). Among the subacute CAG group, 42 (17%) 
had their CAG performed earlier than initially scheduled due to an unstable cardiovascular 
condition (Figure 1).  
The angiography details and treatment of culprit lesion are listed in Table 3. A larger 
proportion of patients in the acute CAG group than in the subacute CAG group had a CAG 
performed. A culprit lesion was identified in 348 (70%) cases with a non-significant difference 
between the 2 groups, but a larger proportion of patients with a culprit lesion in the acute CAG 
group had TIMI flow 0. We found no significant difference in choice of treatment of culprit lesions 
between the 2 groups (Table 3). The median time from randomization to the first revascularization 
was 1.3 hours in the acute CAG group and 51.1 hours in the subacute CAG group (Table 4). 
Patients in the acute CAG group had a median time from randomization to discharge of 3.8 days 
compared with 4.2 days for patients in the subacute CAG group. 
The primary and secondary end-points after 12 months follow-up are shown in Table 5. All 
differences were nonsignificant. We found no difference in all-cause mortality and cumulative 
incidence of the composite endpoint as shown in Figure 2.  
Discussion 
The NONSTEMI trial is the first randomized controlled trial to compare a STEMI-like 
management pathway with conventional therapy in NSTE-ACS patients. It is also the first trial with 
prehospital or immediate hospital arrival enrolment utilizing a combination of ECG and/or POC-
cTn measurement. The ESC and AHA/ACC guidelines on the management of NSTE-ACS patients 
1,2
 recommend an immediate invasive strategy (<2h) in very high-risk NSTE-ACS patients, an early 
invasive strategy (<24h) in high-risk NSTE-ACS patients, and a selective invasive strategy (24-72h) 
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for all other NSTE-ACS patients. The present study compared a STEMI-like management pathway 
with the guideline-recommended strategy, i.e., with patients in the conventional group scheduled for 
CAG within 48-72 hours in general, but within 24 hours if their GRACE score was > 140.  
We found no difference in overall 1-year mortality between the 2 groups (Figure 2). However, 
because the termination of the study was premature, it was not powered to detect a difference in 
mortality. In addition, the overall mortality in both groups was lower than expected, likely because 
our cohort comprised younger patients compared with all-comers with NSTE-ACS (Table 1). 
However, the median age and observed mortality are comparable to those of patients with NSTE-
ACS having PCI performed in Denmark, and comparable to levels reported in previous randomized 
trials 
4-6
.  
The STEMI-like management of NSTE-ACS patients increased the rate of CAG. Some of the 
enrolled NSTE-ACS patients would have avoided the CAG if they had been admitted to the nearest 
hospital for further examination. However, even though the STEMI-like approach implied pre-
treatment with anticoagulants, the STEMI-like management approach did not seem to increase the 
risk of major adverse cardiovascular (Figure 2) or bleeding events within the first year (Table 5). 
Conversely, we observed a trend towards a lower rate of major adverse cardiovascular events within 
the first 30 days (Figure 2). However, the results from the NONSTEMI trial do not differ from 
those reported by other studies comparing acute CAG (< 2 hours) with delayed CAG (8-72 hours) 
4,7,8
. Two exclusion criteria in our study were previous CABG and age > 80 years. This is important 
because data suggest that NSTE-ACS patients aged 80 years or older gain more from an invasive 
than from a conservative strategy 
4,7-10
. In a recently published meta-analysis 
11
, Jobs et al. 
compared 8 randomized controlled trials which all investigated an early versus a delayed invasive 
strategy in patients presenting with NSTE-ACS. They found no significant reduction in mortality 
with the early (1-14h) compared with the delayed invasive strategy (18-87h). In subgroup analyses, 
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however, they found that subacute CAG as associated with a lower mortality in patients with 
elevated cardiac biomarker and high-risk NSTE-ACS patients overall.  
One intriguing observation from the NONSTEMI trial is that 42 (16.7%) patients in the subacute 
CAG group developed an unstable cardiovascular condition and had an accelerated CAG performed 
earlier than scheduled, thus crossing over. This is in line with the Comparison of Two Treatment 
Strategies in Patients With an Acute Coronary Syndrome Without ST Elevation trial (SISCA) 
5
 that 
compared an early invasive strategy (<6h) with a delayed strategy (6-48h) and found that 21 
patients (24%) in the delayed group had their CAG accelerated due to an unstable condition. The 
Immediate Versus Delayed Invasive Intervention for Non-STEMI Patients study (RIDDLE-
NSTEMI) even included re-infarction in the period before catheterization as a component in the 
primary endpoint and found that a total of 10 (6.7%) patients had a re-infarction and 1 patient died 
within 72 hours while awaiting CAG 
7
.  
It is frequently argued that POC-cTn is irrelevant in the high-sensitivity era due to the limitations in 
detecting the subtle changes at levels near the 99
th
 percentile upper reference limit (URL). While 
this is true for the final diagnosis, it may be different when it comes to risk prediction and, thus, 
rule-in for an accelerated invasive strategy. The higher detection limit of POC-cTn compared with 
high-sensitivity troponin (hs-cTn) may be used confidently in prehospital risk-stratification of 
NSTEMI patients. It allows for identification of patients with the highest risk already in the 
prehospital phase or immediately after admission 
3,12,13
. Moreover, an elevated POC-cTn falls in the 
same category as the 52 ng/l rule-in cut point applied in the ESC 0 h/1 h algorithm, implicating that 
an elevated prehospital or immediate POC-cTn should prompt re-routing either directly to the 
coronary care unit or even straight to an invasive center for accelerated CAG, as advocated by the 
ESC and the AHA/ACC 
1,2
. This correlates well with a more aggressive invasive examination 
strategy in patients with the highest risk.  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
9 
 
One additional property of a STEMI-like management pathway in patients with NSTEMI is its 
potential to substantially reduce the patient’s length of stay (LOS) in hospital. The average time 
from randomization to discharge in the acute CAG group was 3.8 days compared with 4.2 days 
(P<0.001) in the subacute CAG group (Table 5). This time reduction may appear very small, but 
with an observed difference in time from randomization to revascularization in our 2 groups of 49.8 
hours, there is potential for further reduction in LOS in the acute CAG group if all patients were 
discharged within 24 hours after CAG as supported by the latest guidelines
1
.  
Even though it was an exclusion criterion that PPCI was already indicated at the time of assessing 
eligibility for the NONSTEMI trial, our cohort consisted of 47 patients (9.5%) with a STEMI 
diagnosis adjudicated by the Endpoint Committee. This could be interpreted as a limitation and an 
uncertainty in the setup. However, 9 (1.8%) developed STEMI after inclusion, and ECG changes in 
ACS can be equivocal. It can be challenging to establish a STEMI diagnosis in patients with 
borderline ST-segment elevations or bundle branch block (BBB). The physician on call assessed all 
patients in our cohort for signs of STEMI utilizing the prehospital ECG and the patient’s history 
recorded over the phone. Cases with suspected STEMI were triaged directly to an invasive centre 
without considering enrolment in the NONSTEMI trial. Thus, the 38 patients who, according to the 
Endpoint Committee, showed signs of STEMI at inclusion were not considered to have ST 
elevations by the attending physician. Had it not been for the POC-cTn, these patients would have 
been missed. POC-cTn can undoubtedly serve as a valuable aid in these situations by detecting 
high-risk patients with ECGs without significant ST changes or an equivocal ECG.  
The NONSTEMI trial does not document a mortality benefit by performing acute CAG in 
patients with NSTE-ACS and documents no increase in major adverse cardiovascular events. The 
study does confirm the feasibility of prehospital diagnosis in NSTE-ACS patients, which may be 
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used to triage these patients directly to an invasive centre to facilitate earlier revascularization and 
earlier discharge.  
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Figure titles and legends 
Title:  
Figure 1 
Flowchart for patients in the NONSTEMI trial 
Legend: 
Acute angiography: Angiography within 2 hours from randomization 
Conventional therapy: Medical treatment and subacute angiography within 72 hours (<24 hours if 
GRACE score >140) 
GRACE: Global Registry of Acute Coronary Events Score 
 
Title:  
Figure 2 
All-cause mortality and cumulative incidence of the composite endpoint; death, re-infarction and 
readmission with congestive heart failure  
Legend: 
Acute angiography: Angiography within 2 hours from randomization  
Conventional therapy: Medical treatment and subacute angiography within 72 hours (<24 hours if 
GRACE score >140)  
GRACE: Global Registry of Acute Coronary Events Score 
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Table 1 
Baseline characteristics and medication 
 Coronary angiography 
Variable 
Valid cases 
496 
Acute  
(n = 245) 
Conventional 
(n = 251) 
Age (years) 496 65.4 (57.3-71.9) 65.9 (58.3-73.0) 
Men 496 166 (67.8%) 165 (65.7%) 
Body Mass Index (Kg/m
2
) 492 26.2 (24.2-29.5) 26.9 (24.2-30.0) 
Risk factors    
Diabetes mellitus 490 36 (14.7 %) 41 (16.7 %) 
Smokers  495 174 (71.0 %) 192 (76.8 %) 
Hypertension 495 105 (42.9 %) 123 (49.2 %) 
Previous acute myocardial infarction 496 30 (12.2 %) 30 (12.0 %) 
Previous revascularization 496 35 (14.3 %) 34 (13.4 %) 
Previous heart failure 495 15 (6.2 %) 16 (6.4 %) 
At admission:    
Symptom duration (hours) 420 3.5 (1.9-6.3) 3.8 (1.6-7.6) 
Heart rate (beats/min) 496 82 (70-96) 84 (72-97) 
Systolic blood pressure (mmHg) 496 148 (130-167) 154 (130-171) 
Medical treatment pre-admission or 
during hospitalization 
   
Aspirin 490 219 (89.4%) 239 (94.4%) 
ADP receptor blocker 490 208 (84.9%) 224 (89.2%) 
     Clopidogrel 490 28 (11.4%) 31 (12.4%) 
     Ticagrelor 490 181 (73.9%) 197 (78.5%) 
Fondaparinux/LMWH 490 7 (2.9%) 192 (76.5%) 
Unfractionated heparin 489 210 (85.7%) 124 (49.4%) 
Abciximab 490 4 (1.6%) 2 (0.8%) 
Bivalirudin 492 104 (42.5%) 33 (13.2%) 
Values are median (interquartile range) or n (%). 
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Table 2 
Inclusion details, biochemical details, and final diagnosis 
 Coronary angiography  
Variable 
Valid 
cases 
Acute  
(n = 245) 
Conventional 
(n = 251) 
Total P value 
Inclusion criteria 
496 
   
0.83 
Only ST-segment depression 72 (29.4%) 70 (27.9%) 142 (28.6%) 
Only POC-cTnT ≥ 50 ng/L* 131 (53.5%) 133 (53.0%) 264 (53.2%) 
ST-segment depression + POC-cTnT ≥ 50 ng/L* 42 (17.1%) 48 (19.1%) 90 (18.1%) 
In-hospital biochemical values on admission      
Creatinine (µmol/L) 496 74 (62-88) 81 (64-96)  0.002 
Troponin I (ng/L) 87 627 (169-2,292) 379 (47-2,010)  0.44 
Troponin T (ng/L) 409 119 (45-314) 128 (55-337)  0.64 
Prehospital biochemical data      
POC-cTnT measured  496 194 (79.2%) 203 (80.9%)  0.64 
Above detection limit (≥40 ng/L / ≥50 ng/L)* 496 171 (69.8%) 179 (71.3%)  0.99 
Final diagnosis  496    
0.27 
Acute coronary syndrome  213 (86.9%) 216 (86.1%) 429 (86.5%) 
NSTEMI  171 (69.8%) 161 (64.1%) 332 (66.9%) 
STEMI  22 (9.0%) 25 (10.0%) 47 (9.5%) 
STEMI, visible at inclusion  20 (8.2%) 18 (7.2%) 38 (7.7%) 
STEMI after inclusion   2 (0.8%) 7 (2.8%) 9 (1.8%) 
Bundle branch block myocardial infarction  2 (0.8%) 3 (1.2%) 5 (1.0%) 
Unstable angina pectoris  18 (7.4%) 27 (10.8%) 45 (9.1%) 
Myocardial injury   20 (8.2%) 21 (8.4%) 41 (8.3%) 
Other  12 (4.9%) 14 (5.6%) 26 (5.2%) 
POC-cTnT: Point-of-care cardiac troponin T 
NSTEMI: Non-ST-segment elevation myocardial infarction 
STD:  ST-segment depression 
STEMI: ST-segment elevation myocardial infarction 
 
*The detection limit in the Cobas h232 instrument was 50 ng/L in the period from June 2012 to November 2015. A software upgrade in 
the Cobas h232 instrument, performed 01.12.15, subsequently lowered the detection limit to 40 ng/L. 
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Table 3 
Angiography, coronary lesions, and revascularization 
 Coronary angiography  
 Acute  
(n = 245) 
Conventional 
(n = 251) 
Total 
(n = 496) 
P value Variable 
Angiography performed  243/245 (99.2%) 218/251 (86.9%) 461/496 (92.9%) < 0.001 
Coronary artery narrowed:      
Left main  15/243 (6.2%) 14/218 (6.4%) 29/461 (6.3%) 0.91 
Left anterior descending  125/243 (51.4%) 129/218 (59.2%) 254/461 (55.4%) 0.096 
Ramus  94/243 (38.7%) 102/218 (46.8%) 196/461 (42.5%) 0.079 
Right  88/243 (36.2%) 99/218 (45.4%) 187/461 (40.6%) 0.045 
Number of narrowed coronary arteries:     
0.0098 
None  61/243 (25.1%) 34/218 (15.6%) 95/461 (20.6%) 
1 81/243 (33.3%) 80/218 (36.7%) 161/461 (34.9%) 
2 67/243 (27.6%) 52/218 (23.9%) 119/461 (25.8%) 
3 34/243 (14.0%) 52/218 (23.9%) 85/461 (18.7%) 
Culprit lesion identified 169/245 (69.0%) 179/251 (71.3%) 348/461 (70.2%) 0.57 
Location of culprit lesion     
0.74 
Left main 7/169 (4.1%) 7/179 (3.9%) 14/348 (4.0%) 
Left anterior descending 65/169 (38.5%) 74/179 (41.3%) 139/348 (39.9%) 
Ramus  56/169 (33.1%) 55/179 (30.7%) 111/348 (31.9%) 
Right 41/169 (24.3%) 43/179 (24.0%) 84/348 (24.1%) 
TIMI flow in culprit lesion  
before revascularization 
   
0.009 
0  53/169 (31.4%) 33/179 (18.4%) 86/348 (24.7%) 
1  11/169 (6.5%) 13/179 (7.3%) 24/348 (6.9%) 
2  14/169 (8.3%) 15/179 (8.4%) 29/348 (8.3%) 
3 91/169 (53.9%) 118/179 (65.9%) 209/348 (60.1%) 
Treatment of culprit lesion     
0.23 
PCI 124/169 (73.4%) 122/179 (68.2%) 246/348 (70.7%) 
CABG 21/169 (12.4%) 36/179 (20.1%) 57/348 (16.4%) 
Hybrid (CABG+PCI) 10/169 (5.9%) 8/179 (4.5%) 18/348 (5.2%) 
Medical treatment recommended 14/169 (8.3%) 13/179 (7.3%) 27/348 (7.8%) 
Values are n/N (%) 
CABG: Coronary artery bypass graft 
PCI: Percutaneous coronary intervention 
TIMI: Thrombolysis in myocardial infarction 
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Table 4 
Timing data 
  Coronary angiography  
 Valid cases 
Acute  
(n = 245) 
Conventional 
(n = 251) 
P value 
EMS call to randomization, h 464 0.9 (0.6-1.1) 0.8 (0.7-1.1) 0.6 
Ambulance arrival to randomization, h  451 0.7 (0.5-1.0) 0.7 (0.5-0.9) 0.4 
Randomization to angiography, h 460 1.0 (0.8-1.4) 47.8 (25.8-67.1) < 0.001 
Randomization to first revascularization, h  320 1.3 (0.9-2.1) 51.1 (25.5-86.4) < 0.001 
Randomization to discharge, days 477 3.8 (2.7-5.0) 4.2 (3.2-5.3) < 0.001 
Patients with ACS 411 3.8 (2.8-4.9) 4.4 (3.63-5.4) < 0.001 
Patients with AMI 369 3.9 (2.9-5.0) 4.4 (3.70-5.4) < 0.001 
Revascularized patients 311 4.0 (3.0-5.0) 4.6 (3.8-6.0) < 0.001 
Revascularized with PCI only  244 3.8 (3.0-4.3) 4.3 (3.7-5.1) < 0.001 
Symptom onset to revascularization 270 6.5 (3.6-13.9) 58.3 (29.6-94.5) < 0.001 
  Place of inclusion  
  Ambulance 
(n = 292) 
Hospital 
(n = 204) 
 
EMS call to randomization, h  464 0.8 (0.6-1.0) 1.2 (0.7-1.5) < 0.001 
Ambulance arrival to randomization, h 451 0.7 (0.5-0.8) 1.0 (0.6-1.3) < 0.001 
Randomization to angiography,  
acute angiography group, h 
243 1.0 (0.8-1.2) 1.3 (0.8-1.8) < 0.001 
Randomization to angiography,  
conventional therapy group, h 
217 49.1 (28.7-67.7) 45.7 (22.2-65.3) 0.1 
Values are median (interquartile range) 
ACS: Acute coronary syndrome 
AMI: Acute myocardial infarction 
EMS: Emergency medical system 
PCI: Percutaneous coronary intervention 
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Table 5 
Clinical events up to 12 months 
 Coronary angiography  
Variable 
Acute 
(n = 245) 
Conventional 
(n = 250) 
Total P Value 
Events within 12 months      
Composite endpoint 25 (10.2%) 29 (11.6%) 54 (10.9%) 0.62 
Death (all-cause) 14 (5.7%) 14 (5.6%) 28 (5.6%) 0.96 
Reinfarction or recurrent MI 7 (2.9%) 10 (4.0%) 17 (3.4%) 0.49 
Readmission with CHF 7 (2.9%) 12 (4.8%) 19 (3.8%) 0.26 
Readmission with stable AP 12 (4.8%) 11 (4.5%) 23 (4.6%) 0.87 
Readmission with unstable AP 7 (2.9%) 9 (3.6%) 16 (3.2%) 0.64 
Readmission with stroke 4 (1.6%) 5 (2.0%) 9 (1.8%) 0.76 
Non-scheduled re-intervention     
PCI 1 (0.4%) 8 (3.2%) 9 (1.8%) 0.02 
CABG 2 (0.8%) 2 (0.8%) 4 (0.8%) 0.98 
Bleeding     
Major bleeding (BARC 3a/3b) 8 (3.3%) 8 (3.2%) 16 (3.2%) 0.97 
Life-threatening (BARC 5) 4 (1.6%) 4 (1.6%) 8 (1.6%) 0.98 
BARC: The Bleeding Academic Research Consortium 
CABG: Coronary artery bypass grafting 
CHF: Congestive heart failure 
MACE: Death, AMI, CHF 
MI: Myocardial infarction 
PCI: Percutaneous coronary intervention 
